Practical Clinical Approach to the Evaluation of Hepatobiliary Disorders in Inflammatory Bowel Disease

Overview

Journal Frontline Gastroenterol

Specialty Gastroenterology

Date 2019 Jul 9

PMID 31281626

Citations 8

Authors

Afif Yaccob

Amir Mari

Affiliations

Soon will be listed here.

Abstract

Hepatobiliary disorders are frequent extraintestinal manifestations in inflammatory bowel disease (IBD) and may appear at any time point during the natural course of the disease. Conceptually, these manifestations can be categorised as: (1) disorders that have an association with IBD; (2) diseases directly and structurally related to intestinal inflammation; (3) diseases related to the adverse effects of IBD treatment; and (4) disorders stemming from the metabolic derangements caused by IBD. The clinical presentations of these disorders range from a mild transient elevation of liver enzymes to liver failure and death. Given this wide differential diagnosis and spectrum of severity, it is understandable that the evaluation of patients with IBD with a hepatobiliary abnormality is often challenging. In this review, we present a concise summary of the common hepatic manifestations seen in patients with IBD and focus on the relevant practical issues encountered by gastroenterologists caring for patients with IBD. A practical clinical approach to the evaluation of liver enzyme abnormalities in patients with IBD is provided based on the predominant enzyme elevation pattern (hepatocellular vs cholestatic), before presenting a working scheme for the prevention of hepatitis B virus (HBV) reactivation in patients with IBD receiving immunosuppressive medications. Finally, we specify several laboratory alterations seen in patients with IBD that can potentially interfere with the interpretation of liver function tests, before defining the specific circumstances when a referral for a hepatological consultation is required for further assessment.

Citing Articles

Hepatobiliary manifestations in patients with ulcerative colitis: a retrospective analysis.

Stratmann K, Aydolmus S, Gu W, Heling D, Spengler U, Terjung B Front Med (Lausanne). 2024; 10:1273797.

PMID: 38249970 PMC: 10796802. DOI: 10.3389/fmed.2023.1273797.

Outcomes of endoscopic retrograde cholangiopancreatography in patients with inflammatory bowel disease: a nationwide study.

Kalligeros M, Kroner P, Farraye F, Desalermos A Int J Colorectal Dis. 2023; 38(1):23.

PMID: 36692549 DOI: 10.1007/s00384-023-04308-w.

Liver biopsy in inflammatory bowel disease patients with sustained abnormal liver function tests: a retrospective single-center study.

Dias E, Andrade P, Lopes S, Goncalves R, Cardoso P, Gaspar R Ann Gastroenterol. 2023; 36(1):54-60.

PMID: 36593810 PMC: 9756023. DOI: 10.20524/aog.2023.0761.

Hepatobiliary manifestations in inflammatory bowel disease: A practical approach.

Nunez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L World J Hepatol. 2022; 14(2):319-337.

PMID: 35317174 PMC: 8891676. DOI: 10.4254/wjh.v14.i2.319.

Liver manifestations and complications in inflammatory bowel disease: A review.

Gaspar R, Castelo Branco C, Macedo G World J Hepatol. 2022; 13(12):1956-1967.

PMID: 35070000 PMC: 8727205. DOI: 10.4254/wjh.v13.i12.1956.

References

Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L . Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut. 2000; 46(2):176-81. PMC: 1727806. DOI: 10.1136/gut.46.2.176. View

Bernstein C, Blanchard J, Leslie W, Wajda A, Yu B . The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000; 133(10):795-9. DOI: 10.7326/0003-4819-133-10-200011210-00012. View

Schoon E, Muller M, Vermeer C, Schurgers L, Brummer R, Stockbrugger R . Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?. Gut. 2001; 48(4):473-7. PMC: 1728221. DOI: 10.1136/gut.48.4.473. View

Bernstein C, Leslie W, LeBoff M . AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124(3):795-841. DOI: 10.1053/gast.2003.50106. View

Lee W . Drug-induced hepatotoxicity. N Engl J Med. 2003; 349(5):474-85. DOI: 10.1056/NEJMra021844. View

van Hogezand R, Hamdy N . Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl. 2006; (243):59-64. DOI: 10.1080/00365520600664276. View

Mendes F, Levy C, Enders F, Loftus Jr E, Angulo P, Lindor K . Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2006; 102(2):344-50. DOI: 10.1111/j.1572-0241.2006.00947.x. View

Kimura Y, Takada T, Kawarada Y, Nimura Y, Hirata K, Sekimoto M . Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007; 14(1):15-26. PMC: 2784509. DOI: 10.1007/s00534-006-1152-y. View

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2007; 45(2):507-39. DOI: 10.1002/hep.21513. View

10.

Chang C, Schiano T . Review article: drug hepatotoxicity. Aliment Pharmacol Ther. 2007; 25(10):1135-51. DOI: 10.1111/j.1365-2036.2007.03307.x. View

11.

Leeds J, Horoldt B, Sidhu R, Hopper A, Robinson K, Toulson B . Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand J Gastroenterol. 2007; 42(10):1214-20. DOI: 10.1080/00365520701365112. View

12.

Lee W, Squires Jr R, Nyberg S, Doo E, Hoofnagle J . Acute liver failure: Summary of a workshop. Hepatology. 2008; 47(4):1401-15. PMC: 3381946. DOI: 10.1002/hep.22177. View

13.

Kuwabara A, Tanaka K, Tsugawa N, Nakase H, Tsuji H, Shide K . High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2008; 20(6):935-42. DOI: 10.1007/s00198-008-0764-2. View

14.

Roda G, Caponi A, Belluzzi A, Roda E . Severe cholestatic acute hepatitis following azathioprine therapy in a patient with ulcerative pancolitis. Dig Liver Dis. 2009; 41(12):914-5. DOI: 10.1016/j.dld.2009.03.004. View

15.

Navaneethan U, Shen B . Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16(9):1598-619. DOI: 10.1002/ibd.21219. View

16.

Loras C, Gisbert J, Minguez M, Merino O, Bujanda L, Saro C . Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010; 59(10):1340-6. DOI: 10.1136/gut.2010.208413. View

17.

Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S . Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis. 2011; 43 Suppl 1:S40-8. DOI: 10.1016/S1590-8658(10)60691-3. View

18.

Gisbert J, Chaparro M, Esteve M . Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33(6):619-33. DOI: 10.1111/j.1365-2036.2010.04570.x. View

19.

Park S, Yang S, Lim Y, Shim J, Yang D, Jung K . Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis. 2012; 18(11):2004-10. DOI: 10.1002/ibd.22905. View

20.

. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85. DOI: 10.1016/j.jhep.2012.02.010. View